Pitiríase versicolor

Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. Resumo

Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. Resumo

Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004 Nov;51(5):785-98. Resumo

Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9. Resumo

1. Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. Resumo

2. James WD, Berger TG, Elston DM. Andrews' diseases of the skin: clinical dermatology. 10th ed. Philadelphia, PA: Elsevier; 2006.

3. Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis. 2006 Apr;19(2):139-47. Resumo

4. Aljabre SH, Alzayir AA, Abdulghani M, et al. Pigmentary changes of tinea versicolor in dark-skinned patients. Int J Dermatol. 2001 Apr;40(4):273-5. Resumo

5. Pontasch MJ, Kyanko ME, Brodell RT. Tinea versicolor of the face in black children in a temperate region. Cutis. 1989 Jan;43(1):81-4. Resumo

6. Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. Resumo

7. Faergemann J, Fredriksson T. Tinea versicolor with regard to seborrheic dermatitis: an epidemiological investigation. Arch Dermatol. 1979 Aug;115(8):966-8. Resumo

8. Odland GF, Kraning KK. Prevalence, morbidity, and cost of dermatological diseases (editorial). J Invest Dermatol. 1979;73(5):395-401.Texto completo  Resumo

9. Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol. 1981 Nov;117(11):752-3. Resumo

10. Balestri R, Rech G, Piraccini BM, et al. Pityriasis versicolor during anti-TNF-α monoclonal antibody therapy: therapeutic considerations. Mycoses. 2012 Sep;55(5):444-6. Resumo

11. Morishita N, Sei Y. Microreview of pityriasis versicolor and Malassezia species. Mycopathologia. 2006 Dec;162(6):373-6. Resumo

12. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004 Nov;51(5):785-98. Resumo

13. Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother. 2005 Feb;6(2):165-78. Resumo

14. Conklin RJ. Common cutaneous disorders in athletes. Sports Med. 1990 Feb;9(2):100-19. Resumo

15. Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in culture of Pityrosporum. J Invest Dermatol. 1978 Sep;71(3):205-8. Resumo

16. De Luca C, Picardo M, Breathnach A, et al. Lipoperoxidase activity of Pityrosporum: characterisation of by-products and possible role in pityriasis versicolor. Exp Dermatol. 1996(Feb);5(1):49-56. Resumo

17. Karaoui R, Bou-Resli M, Alzaid NS, et al. Tinea versicolor: ultrastructural studies on hypopigmented and hyperpigmented skin. Dermatologica. 1981;162(2):69-85. Resumo

18. Borgers M, Cauwenbergh G, Van De Ven M, et al. Pityriasis versicolor and Pityrosporum ovale: morphogenetic and ultrastructural considerations. Int J Dermatol. 1987 Nov;26(9):586-9. Resumo

19. Thoma W, Kramer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):147-52. Resumo

20. Allen HB, Charles CR, Johnson BL. Hyperpigmented tinea versicolor. Arch Dermatol. 1976 Aug;112(8):1110-2. Resumo

21. Galdari I, El Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol. 1992 Apr;31(4):253-6. Resumo

22. Dotz WI, Henrickson DM, Yu GS, et al. Tinea versicolor: a light and electron microscopic study of hyerpigmented skin. J Am Acad Dermatol. 1985 Jan;12(1 Pt 1):37-44. Resumo

23. Kamalam A, Thambiah AS, Bagavandas M, et al. Mycosis in India: study in Madras. Trans R Soc Trop Med Hyg. 1981;75(1):92-100. Resumo

24. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80. Resumo

25. Hafez M, el-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica. 1985;171(2):86-8. Resumo

26. He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses. 2008 Jan;51(1):55-62.Texto completo  Resumo

27. Stein DH. Superficial fungal infections. Pediatr Clin North Am. 1983 Jun;30(3):545-61. Resumo

28. Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):300-5. Resumo

29. Lohoue Petmy J, Lando AJ, Kaptue L, et al. Superficial mycoses and HIV infection in Yaounde. J Eur Acad Dermatol Venereol. 2004 May;18(3):301-4. Resumo

30. Spence-Shishido A, Carr C, Bonner MY, et al. In vivo Gram staining of tinea versicolor. JAMA Dermatol. 2013 Aug;149(8):991-2. Resumo

31. Yang S, Makredes M, O'Donnell P, et al. A case of Hansen Disease presenting as tinea versicolor. Dermatol Online J. 2013 Apr 15;19(4):7.Texto completo  Resumo

32. El-Gothamy Z, Abdel-Fattah A, Ghaly AF. Tinea versicolor hypopigmentation: histochemical and therapeutic studies. Int J Dermatol. 1975 Sep;14(7):510-5. Resumo

33. Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy. 1999 May;54(5):413-9.Texto completo  Resumo

34. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9. Resumo

35. Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. Resumo

36. Mills OH Jr, Kligman AM. Letter: Tretinoin in tinea versicolor. Arch Dermatol. 1974 Oct;110(4):638. Resumo

37. Shi TW, Ren XK, Yu HX, et al. Roles of adapalene in the treatment of pityriasis versicolor. Dermatology. 2012;224(2):184-8. Resumo

38. Wedig JH, Kennedy GL Jr, Jenkins DH, et al. Teratologic evaluation of dermally applied zinc pyrithione on swine. Toxicol Appl Pharmacol. 1976 May;36(2):255-9. Resumo

39. Nolen GA, Patrick LF, Dierckman TA. A percutaneous teratology study of zinc pyrithione in rabbits. Toxicol Appl Pharmacol. 1975 Mar;31(3):430-3. Resumo

40. Kokturk A, Kaya TI, Ikizoglu G, et al. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat. 2002 Dec;13(4):185-7. Resumo

41. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg. 2014 Mar-Apr;18(2):79-90. Resumo

42. Köse O, Bülent Taştan H, Riza Gür A, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat. 2002 Jun;13(2):77-9. Resumo

43. Wahab MA, Ali ME, Rahman MH, et al. Single dose (400 mg) versus 7 day (200 mg) daily dose itraconazole in the treatment of tinea versicolor: a randomized clinical trial. Mymensingh Med J. 2010 Jan;19(1):72-6. Resumo

44. Medicines and Healthcare Products Regulatory Agency. Press release: oral ketoconazole-containing medicines should no longer be used for fungal infections. July 2013 [internet publication].Texto completo

45. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013 [internet publication].Texto completo

46. US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. May 2016 [internet publication].Texto completo

47. Helou J, Obeid G, Moutran R, et al. Pityriasis versicolor: a case of resistance to treatment. Int J Dermatol. 2014 Feb;53(2):e114-6. Resumo

48. Faergemann J, Djarv L. Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis. 1982 Oct;30(4):542-5;550. Resumo

49. Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis. 1984 Nov;34(5):470-1. Resumo

50. Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002 Jan;138(1):69-73.Texto completo  Resumo

51. Jung EG, Bohnert E. Mechanism of depigmentation on pityriasis versicolor alba. Arch Dermatol Res. 1976 Oct 27;256(3):333-4. Resumo

52. Rubin AI, Bagheri B, Scher RK. Six novel antimycotics. Am J Clin Dermatol. 2002;3(2):71-81. Resumo

53. Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009 Dec;61(6):971-6. Resumo